Pathogenesis of Increased Risk of Thrombosis in Cancer

Hau C. Kwaan; Simrit Parmar; Jun Wang

doi:10.1055/s-2003-40966

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2003; 29(3): 283-290
DOI: 10.1055/s-2003-40966

Pathogenesis of Increased Risk of Thrombosis in Cancer

Hau C. Kwaan¹ , Simrit Parmar² , Jun Wang²

Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois
²Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois

Abstract

ABSTRACT

Since the observations of Trousseau, not only has the association of cancer and thrombosis been widely recognized but its pathogenesis is now better understood. Attention to the tumor cell as an important source of procoagulants has also contributed to our knowledge of this problem. Tumor cells express tissue factor (TF) and a cancer procoagulant (CP). TF is dormant in the living cell. However, it is activated during apoptosis of the cell, initiating the coagulation cascade and leading to thrombin generation. Because increased apoptosis occurs during treatment with chemotherapeutic agents, hormones, radiation, and hematopoietic growth factors, as well as when there is rapid tumor proliferation, the thrombosis risk is heightened accordingly. These developments have obvious basic and clinical implications.

KEYWORDS

Thrombosis - cancer - apoptosis - tissue factor - fibrinolysis

Full Text

References

REFERENCES

1 Trousseau A. Phlegmasia alba dolens. In: Clinique Medicale de l'Hotel Dieu de Paris, 2nd ed. Paris: Bailliere 1865 : 654-712
2 Billroth T. Lectures on surgical pathology and therapeutics. In: A Handbook for Students and Practitioners (translated) London: The New Sydenham Society 1877-1878
3 Kwaan H C, Lo R, McFadzean A JS. Antifibrinolytic activity in primary carcinoma of the liver. Clin Sci . 1959; 18 250-261
4 Rickles F R, Levine M N, Edwards R L. Hemostatic alterations in cancer patients. Cancer Metastasis Rev . 1992; 11 237-248
5 Falanga A, Barbui T, Rickles F R. et al . Guidelines for clotting studies in cancer patients. Thromb Haemost . 1993; 70 343-350
6 Virchow R. Phlogose und Thrombose in Gefäβsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin Virchow R, ed. Frankfurt: Von Meidinger Sohn 1856: 458
7 Rickles F R, Levine M N, Dvorak H F. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, et al, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4th ed Philadelphia, PA: Lippincott Williams & Wilkins 2001: 1131-1152
8 O'Meara R AQ, Thornes R D. Some properties of the cancer coagulative factor. Ir J Med Sci . 1961; 6 106-112
9 O'Meara R AQ. Coagulative properties of cancers. Ir J Med Sci . 1958; 6 474-479
10 Dvorak H F, VanDewater L, Bitzer A M. et al . Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res . 1983; 43 4334-4342
11 Carmeliet P, Collen D. Tissue factor. Int J Biochem Cell Biol . 1998; 30 661-667
12 Greeno E W, Bach R R, Moldow C F. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. Lab Invest . 1996; 75 281-289
13 Edwards R L, Morgan D L, Rickels F R. Animal tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost . 1990; 63 133-138
14 Edwards R L, Silver J, Rickles F R. Human tumor procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society of Thrombosis and Haemostasis. Thromb Haemost . 1993; 69 205-213
15 Rickles F R, Hair G A, Schmeizl M. et al . All-trans-retinoic acid (ATRA) inhibits the expression of tissue factor in human progranulocytic leukemia cells (Abst). Thromb Haemost . 1993; 69 573
16 Wang J, Weiss I, Svoboda K. et al . Thrombogenic role of cells undergoing apoptosis. Br J Haematol . 2001; 115 382-391
17 Gale A J, Gordon S G. Update on tumor cell procoagulant factors. Acta Haematol . 2001; 106 25-32
18 Gordon S G, Cross B A. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Cancer Res . 1990; 50 6229-6234
19 Kozwich D L, Kramer L C, Mielicki W P. et al . Application of cancer procoagulant as an early detection tumor marker. Cancer . 1994; 74 1367-1376
20 Mielicki W P, Tenderenda M, Rutkowski P. et al . Activation of blood coagulation and activity of cancer procoagulant (EC 3.4.22.26) in breast cancer patients. Cancer Lett . 1999; 146 61-66
21 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant and tissue factor are differently modulated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood . 1998; 92 143-151
22 Falanga A, Consonni R, Marchetti M. et al . Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by retinoic acid. Leukemia . 1994; 8 156-158
23 Koyama T, Hirosawa S, Kawamata N. et al . All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: distinct expression of thrombomodulin and tissue factor in human leukemic cells. Blood . 1994; 84 3001-3009
24 De Stefano V, Teofili L, Sica S. et al . Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood . 1995; 86 3535-3541
25 Nierodzik M LR, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol . 1996; 92 452-457
26 Yoshida E, Verrusio E N, Mihara H. et al . Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. Cancer Res . 1994; 54 3300-3304
27 Yoshida E, Verrusio E N, Mihara H. et al . Thrombin stimulates expression of the receptor for urokinase-type plasminogen activator in DU-145 prostate cancer cells. Fibrinolysis Proteolysis . 1997; 11 147-154
28 Nierodzik M L, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vivo and tumor metastasis in vivo. Cancer Res . 1992; 52 3267-3272
29 McNamara C A, Sarembok I J, Gimple L W. Thrombin stimulation of smooth muscle proliferation is mediated by a proteolytic, receptor-mediated mechanism. J Clin Invest . 1992; 91 94-98
30 Nierodzik M L, Plotkin A, Kajumo F. et al . Thrombin stimulates tumor-platelet adhesion in vivo. J Clin Invest . 1991; 87 229-236
31 Nierodzik M L, Bain R M, Liu L X. et al . Presence of the seven transmembrane thrombin receptor on human tumour cells: effect of activation on tumour adhesion to platelets and tumour tyrosine phosphorylation. Br J Haematol . 1996; 92 452-457
32 Klepfish A, Greco M A, Karpatkin S. Thrombin stimulates melanoma tumor-cells binding to endothelial cells and sub-endothelial matrix. Int J Cancer . 1993; 53 978-982
33 Wun T C, Kretzmer K K, Girard T J. et al . Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of the three tandem Kunitz-type inhibitory domains. J Biol Chem . 1988; 263 6001-6004
34 Girard T J, Warren L A, Novotny W F. et al . Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature . 1989; 338 518-520
35 Rao L V, Rapaport S I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood . 1987; 69 645-651
36 Lindahl A K, Ødegaard O R, Sandset P M. et al . Coagulation inhibition and activation in pancreatic cancer. Cancer . 1992; 70 2067-2072
37 Lindahl A K, Sandset P M, Abildgaard U. et al . High levels of extrinsic pathway inhibitor and low levels of other coagulation inhibitors in advanced malignant disease. Acta Chir Scand . 1989; 155 389-393
38 Iversen N, Lindahl A-K, Abildgaard U. Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol . 1998; 102 889-895
39 Wojtukiewicz M Z, Zacharski L R, Rucinska M. et al . Expression of tissue factor and tissue factor pathway inhibitor in situ in laryngeal carcinoma. Thromb Haemost . 1999; 82 1659-1662
40 Bajaj M S, Kuppuswamy M N, Saito H. et al . Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitors: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA . 1990; 87 8869-8873
41 Ameri A, Kuppuswamy M N, Basu S. et al . Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood . 1992; 79 3219-3226
42 Kwaan H C. The plasminogen-plasmin system in malignancy. Cancer Met Rev . 1992; 11 291-311
43 Carroll V A, Binder B R. The role of the plasminogen activation system in cancer. Semin Thromb Hemost . 1999; 25 183-197
44 Heittiarachchi R JK, Lok J, Prins M H. et al . Undiagnosed malignancy in patients with DVT. Incidence, risk indicators and diagnosis. Cancer . 1998; 83 100-105
45 Sørenson H, Mallemakjaer L, Steffen F H. et al . The risk of diagnosis of cancer after primary DVT or PE. N Engl J Med . 1998; 338 1169-1174
46 Baron J A, GridleyG, Weiderpass E. et al . Venous thromboembolism and cancer. Lancet . 1998; 351 1077-1080
47 Monreal M, Prandoni P. Venous thromboembolism as first manifestation of cancer. Semin Thromb Haemost . 1999; 25 131-136
48 Picioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol . 2001; 106 13-17
49 Tallman M S, Kwaan H C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood . 1992; 79 543-553
50 Golomb H, Rowley J D, Vardiman J W. et al . Microgranular acute promyelocytic acute leukemia: a distinct clinical, ultrastructural and cytogenetic entity. Blood . 1980; 55 253-259
51 Menell J S, Cesarman G M, Jacovina A T. et al . Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med . 1999; 340 994-1004
52 Falanga A, Alessio M G, Donati M B. et al . A new procoagulant in acute leukemia. Blood . 1988; 71 870-875
53 Donati M B, Falanga A, Consonni R. et al . Cancer procoagulant in non lymphoid leukemia: relationship of enzyme detection to disease activity. Thromb Haemost . 1990; 64 11-16
54 Bennett B, Booth A, Croll A. et al . The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol . 1989; 71 511-517
55 Francis R B, Seyfert U. Tissue plasminogen activator antigen and activity in disseminated intravascular coagulation. Clinicopathologic correlations. J Lab Clin Med . 1987; 110 541-547
56 Stephens R, Alitalo R, Tapiovaara H. et al . Production of an active urokinase by leukemia cells. A novel distinction from cell lines of solid tumors. Leuk Res . 1988; 12 419-422
57 Naschitz J E, Yeshurn D, Eldar S. et al . Diagnosis of cancer associated vascular disorders. Cancer . 1996; 77 1759-1767
58 Levine M N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost . 1997; 78 133-136
59 Doll D C, Yarbro J W. Vascular toxicity associated with antineoplastic agents. Semin Oncol . 1992; 19 580-596
60 von Templehoff F G, Dietrich M, Hommel G. et al . Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer. J Clin Oncol . 1996; 14 2560-2568
61 Saphner T, Tormey D C, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol . 1991; 9 286-294
62 Goodnough L T, Saito H, Manni A. et al . Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer . 1984; 54 1264-1268
63 Oberhoff C, Winkler U H, Tauchert A M. et al . Adjuvant CMF chemotherapy in patients with breast cancer-results on blood coagulation and fibrinolysis. Zentralbl Gynäkol . 1997; 119 211-217
64 Bertomeu M C, Gallo S, Lauri D. et al . Chemotherapy enhances endothelial cell reactivity to platelets. Clin Exp Met . 1990; 8 511-518
65 Pemberton K D, Melissari E, Kakkar V V. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis . 1993; 4 935-942
66 Jankowski J, Ramlau C, Kopczynski Z. et al . Influence of tamoxifen on plasma coagulation and serous fibrinolysis. Eur J Gynaecol Oncol . 1993; 14(Suppl) 155-158
67 Cohen L F, Balow J E, Magrath I T. et al . Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med . 1980; 68 486-491
68 Haas M, Ohler L, Watzke H. et al . The spectrum of acute renal failure in tumor lysis syndrome. Nephrol Dial Transplant . 1999; 14 776-779
69 Fleming D R, Doukas M A. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma . 1992; 8 315-318
70 Jasek A M, Day H G. Acute spontaneous tumor lysis syndrome. Am J Hematol . 1994; 47 129-131